Development of interferon antibodies during the treatment of skin diseases with low-dose recombinant interferon alpha-2a
Corbillet, V.; Celerier, P.; Lebon, P.; Litoux, P.; Dreno, B.
Annales de Medecine Interne 146(6): 399-403
1995
ISSN/ISBN: 0003-410X PMID: 8597337 Document Number: 444885
In this study, we determined the frequency of interferon antibodies in patients with skin diseases treated with low doses of recombinant interferon alpha 2a (1.5 - 18 x 10(6) IU). We assayed serum specimens from 181 patients with malignant melanoma or cutaneous T cell lymphomas (78 patients treated with recombinant interferon alpha 2a and 103 patients in control group) for interferon antibodies before treatment and every 6 months for at least 18 months. Neutralizing interferon alpha 2a antibodies were detected in 27 of 77 treated patients (35%), but none in control group (p < 10(-6)): 38.2% in melanoma and 12.5% in T cell lymphomas. However antibody formation was not correlated with nonresponse or with frequency of interferon antibodies in patients receiving the combined therapy: interleukin-2 and interferon alpha 2a.